Significant Milestone Reached in ACL Digital Pathology Study
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The study aims to validate the technology across various tissue types and cancers, generating real-world data to support workflow optimization and regulatory submissions. CEO Dr. Camile Farah highlighted the achievement as a demonstration of the platform's maturity and potential impact on pathology. The collaboration with ACL is expected to enhance the integration of InForm™ into existing laboratory workflows and support future commercial discussions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Optiscan Initiates Head and Neck Cancer Study in the US
- Preliminary Final Report
- Optiscan Signs New Research Agreement for Breast Study
- Head and Neck Study Progressing Ahead of Schedule
- Optiscan Launches InSpecta Device for Veterinary Medicine
Later from Optiscan Imaging
- Optiscan Lodges U.S. FDA 510(k) Submission for InForm
- Optiscan Lodges U.S. FDA 510(k) Submission for InVue
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging